Shanghai Junshi Biosciences, a Chinese drug developer backed by Hillhouse Capital, is seeking to raise up to HK$3.2 billion ($414 million) through a Hong Kong IPO.
The company – which is listing under provisions that allow biotech companies to sell shares on the Hong Kong Stock Exchange despite having little or no revenue – is planning to sell 158.9 million shares...
Xyb2b.com, a B2B platform that helps Chinese e-commerce companies source products from overseas, has completed an extended Series B round of funding worth $100 million.
Beijing Ubox Online Technology, a Chinese vending machine manager, has received RMB1.6 billion ($226 million) in funding from Ant Financial Services Group and Primavera Capital Group.
CITIC Capital has scaled up for its latest China fund, raising 75% more capital than in the previous vintage. The buyout-focused GP expects tighter liquidity to drive more corporate carve-outs
Tala, a US financial technology provider looking to expand its microlending operations in India, has raised a $110 million Series D round from a group including PayPal Ventures.